Relationship Between PTEN and Glycemic Variability and Outcome in Critically Ill Patients (GLUPTEN)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01796847|
Recruitment Status : Completed
First Posted : February 22, 2013
Last Update Posted : November 7, 2017
Glycemic variability in critically ill patients is a recognized negative prognostic factor. The molecular mechanisms determining inter-patients variability in glucose metabolism during stress are not fully understood. The Phosphatase and Tensin homolog (PTEN) is known to influence glucose homeostasis by interfering in intracellular insulin signaling.
Aim of this study is to ascertain whether differential expression of PTEN in critically ill patients correlates with glycemic variability and clinical outcome.
|Condition or disease|
|Critical Illness Hyperglycemia|
|Study Type :||Observational|
|Actual Enrollment :||20 participants|
|Official Title:||Influence of PTEN on Glycemic Variability and Clinical Outcome in the Critically Ill Patient.|
|Study Start Date :||December 2012|
|Actual Primary Completion Date :||December 2014|
|Actual Study Completion Date :||May 2015|
- Length of ICU stay [ Time Frame: Day 1 up to day 28 ]
- Glycemic variability as expressed by standard deviation of the glycemia measurements [ Time Frame: Day 1 up to day 28 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01796847
|University of Rome La Sapienza, University Hospital|
|Rome, Italy, 00185|
|Principal Investigator:||Alessandro Laviano, MD||Sapienza University of Rome|